Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | THRB | P10828 | 1/20 | 0.74 |
| ▸ | BLM | P54132 | 3/20 | 0.69 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.50 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.46 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | XBP1 | P17861 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29878134 | 1.00 | POLB (0.74) | POLBMAPTTHRBBLMPKM | |
| SCHEMBL22420582 | 0.99 | POLB (0.73) | POLBMAPTTHRBBLMPKM | |
| SCHEMBL29878219 | 0.99 | POLB (0.73) | POLBMAPTTHRBBLMPKM | |
| SCHEMBL17752106 | 0.98 | POLB (0.76) | POLBMAPTTHRBBLMPKM | |
| SCHEMBL29878400 | 0.98 | POLB (0.76) | POLBMAPTTHRBBLMPKM | |
| SCHEMBL17748317 | 0.95 | POLB (0.76) | POLBMAPTTHRBBLMPKM | |
| SCHEMBL23499867 | 0.92 | POLB (0.65) | POLBMAPTTHRBBLMPKM | |
| SCHEMBL29878007 | 0.92 | POLB (0.65) | POLBMAPTTHRBBLMPKM | |
| SCHEMBL23519982 | 0.92 | POLB (0.79) | POLBMAPTTHRBBLMPKM | |
| SCHEMBL23499858 | 0.92 | POLB (0.65) | POLBMAPTTHRBBLMPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486246-B2 | Replication protein A (RPA)-DNA interaction inhibitors | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2025-12-02 | — | — | US | disclosed |
| US-20230056729-A1 | REPLICATION PROTEIN A (RPA)-DNA INTERACTION INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2023-02-23 | — | — | US | disclosed |
| WO-2021119242-A1 | REPLICATION PROTEIN A (RPA)-DNA INTERACTION INHIBITORS | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2021-06-17 | — | — | WO | disclosed |
| US-10774063-B2 | Materials and method for inhibiting replication protein A and uses thereof | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-09-15 | — | — | US | disclosed |
| WO-2016077752-A2 | MATERIALS AND METHOD FOR INHIBITING REPLICATION PROTEIN A AND USES THEREOF | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774063-B2 | Materials and method for inhibiting replication protein A and uses thereof | RPA1, RPA3, PCNA | POLB 97/4885MAPT 4169/4885THRB 4257/4885 |
| US-12486246-B2 | Replication protein A (RPA)-DNA interaction inhibitors | RPA1, RPA3, RPAP1 | POLB 49/4885MAPT 3496/4885THRB 4209/4885 |
| US-20230056729-A1 | REPLICATION PROTEIN A (RPA)-DNA INTERACTION INHIBITORS | RPA1, RPA3, RPAP1 | POLB 49/4885MAPT 3496/4885THRB 4209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.